Iwamura got off to a solid start hittingFor more information please visit or shopGallo WineryAngie Galimanis Copyright Business Wire 2009Nto whose board he was elected in NovemberI think the restrictions are so severe on the property6 percent Reporting by Atul Prakash StocksIDnN16287370 The scandal has hit Indian stocksI feel like I'm just rehashing statistics hereSuper Bowl IX in New Orleans LA against the Minnesota Vikings Lastly we look to round out the relieversFrancis College in 1990 and his MBA fromAdelphi University in 1993.Speaking of Mr Pino's appointment, Dr. Studin said, "We couldn't be happierthat Richard agreed to join our Company. His experience covers all aspects ofthe finance, treasury and accounting roles, and includes strategic planning,mergers and acquisitions, all roles that he will fulfill while at Scarguard.He will be a key part of Scarguard's growth as a company." About Scarguard Labs, LLC.Scarguard Labs, LLC is a closely held pharmaceutical company specializing indermatological medications employing an internationally patented deliverysystem designed to enhance drug effectiveness utilizing a multi-technologyapproach. Our flagship product, Scarguard, is the most frequently dispensedproduct for scars in plastic surgery offices since 2001. In addition, it canbe found in most pharmacies, drug distributors and major grocery chainsthroughout the United States. 
We have multiple topical prescription andnon-prescription drugs in the marketplace, or in varying stages ofdevelopment. For more information, please visit our website at Contact:Richard E. PinoChief Financial Officer /Investor RelationsScarguard Labs, Investor Relations:John McNamaraCameron Associates(212) 245-8800 Ext. SOURCEScarguard Labs, LLCRichard E.
Pino, Chief Financial Officer /Investor Relations, Scarguard Labs,LLC, 1-516-482-8050, ; Investor Relations, JohnMcNamara, of Cameron Associates for Scarguard Labs, LLC, 1-212-245-8800 Ext.205, . Global Med Technologies(R)' Inlog Subsidiary Licensed EdgeTrack to 62 FrenchHospitals in 2008, Including 19 Hospitals in Q4 2008Transfusion Service Software Confirms its Leading Position in French HospitalMarket with More Than 130 InstallationsDENVER, Jan. 14 /PRNewswire-FirstCall/ Global Med Technologies(R), Inc.("Global Med" or the "Company") (OTC Bulletin Board: GLOB), an internationale-Health, medical information technology company, today announced that itssubsidiary, Inlog, has licensed its EgdeTrack Transfusion Services Software(marketed as "Hemo Serveur" in France) to nineteen additional hospitals duringthe fourth quarter of 2008.(Logo: http://)EdgeTrack Transfusion Management Software provides a complete transfusionrecord, including patient information, pre and post-transfusion data tracking,tracing of blood components and comprehensive tracking of orders, making iteasier for hospital technicians to provide appropriate blood products forpatients.EdgeTrack's complete feature set and configurability will assisteach of these hospitals in meeting their diverse needs and improve theirprocesses.In Q4 of 2008, the following French healthcare organizations chose Inlog fortheir blood traceability and transfusion management: Hospices Civils de Lyon(4 hospitals), Polyclinique de la Ligne Bleue (Epinal), Vienne Hospital, DreuxHospital, Centre Medical de Forcilles, Bourgoin Jallieu Hospital, TarareHospital, Laval Hospital, Villefranche-sur-Saone Hospital, CAPIO group (4hospitals), Centre Anti-Cancer Paul Papin (Angers), Aubenas Hospital, OyonnaxHospital.These hospitals join the 43 other establishments that choseEdgeTrack last year, including 21 Assistance Publique - Hopitaux de Paris("AP-HP") hospitals, one of the largest healthcare information technologyprojects ever undertaken in Europe. Since EdgeTrack was introduced into the market in 1995 as "Hemo Serveur", ithas become a leading hospital transfusion and traceability informationmanagement system in France with more than 130 licensed hospitals.EdgeTrackeasily connects with most laboratory information systems (LIS) and hospitalinformation systems (HIS).EdgeTrack interchanges data with all major bloodbanking information systems including Inlog's own EdgeBlood (which isinstalled in 100 of the French Blood Establishment's "EFS" Blood DonorCenters).Will Willman, Senior Vice President of Sales and Marketing EU/ME/Asia atGlobal Med Technologies, commented, "We are very pleased to have such wideFrench market acceptance of our transfusion software.EdgeTrack has beensteadily gaining market share, which is now approximately 50 of the Frenchpublic hospitals that have transfusion software installed.EdgeTrack hasbecome a de-facto standard for French public hospitals that require a proventransfusion solution with quality installation, training and support services. We look forward to helping each of these hospitals continue to provideexcellent and advanced transfusion services to their physicians and patients."About Global Med Technologies, Inc.Global Med Technologies(R), Inc. is an international medical software companywhich develops regulated and non-regulated products and services for thehealthcare industry.As a leading provider of blood and laboratory systemsand services, Global Med's products are deployed in 20 countries and serveover 1,600 transfusion centers, blood banks and laboratories.Global Med's domestic companies are Wyndgate Technologies(R), a leader insoftware products and services for donor centers and hospital transfusionservices; eDonor(R), which offers web-based donor relationship managementsystems; and PeopleMed(TM), Inc., which implements cost-effective softwarevalidation, consulting and compliance solutions to hospitals and donorcenters.Global Med's European subsidiary, Inlog, SA, is a leading developer of donorcenter and transfusion management systems as well as cellular therapysoftware, laboratory information systems and quality assurance medicalsoftware systems internationally.For more information about Global Med's products and services, please call800-996-3428 or visit news release may include statements that constitute forward-lookingstatements, usually containing the words "believe," "estimate," "project,""expects" or similar expressions.These statements are made pursuant to thesafe harbor provisions of the Private Securities Litigation Reform Act of1995.Forward-looking statements inherently involve risks and uncertaintiesthat could cause actual results to differ materially from the forward-lookingstatements.By making these forward-looking statements, the Companyundertakes no obligation to update these statements for revisions or changesafter the date of this news release.SOURCEGlobal Med Technologies, Inc.Michael I Ruxin, M.D. of Global Med Technologies, Inc., 1-303-238-2000,; or Investors, Paul Holm, President of portfolio pr,1-212-888-4570, , for Global Med Technologies, Inc..
